Revance Therapeutics (RVNC) Downgraded by BidaskClub to Strong Sell

Revance Therapeutics (NASDAQ:RVNC) was downgraded by equities researchers at BidaskClub from a “sell” rating to a “strong sell” rating in a report issued on Wednesday.

Several other brokerages have also recently weighed in on RVNC. Guggenheim reiterated a “neutral” rating and issued a $42.00 price target on shares of Revance Therapeutics in a research report on Thursday, January 4th. Mizuho reiterated a “buy” rating and issued a $54.00 price target on shares of Revance Therapeutics in a research report on Friday, January 5th. Cantor Fitzgerald set a $50.00 target price on Revance Therapeutics and gave the stock a “buy” rating in a research report on Thursday, January 4th. Barclays set a $40.00 target price on Revance Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, December 19th. Finally, Cowen set a $55.00 target price on Revance Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, January 17th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $44.30.

Revance Therapeutics (NASDAQ:RVNC) opened at $30.60 on Wednesday. The firm has a market capitalization of $947.73, a price-to-earnings ratio of -8.03 and a beta of 1.36. Revance Therapeutics has a 52-week low of $18.00 and a 52-week high of $37.45.

In related news, CEO L Daniel Browne sold 7,600 shares of the business’s stock in a transaction dated Wednesday, November 22nd. The stock was sold at an average price of $24.94, for a total transaction of $189,544.00. Following the completion of the transaction, the chief executive officer now directly owns 133,188 shares in the company, valued at $3,321,708.72. The transaction was disclosed in a document filed with the SEC, which is available through this link. 18.86% of the stock is owned by insiders.

A number of institutional investors have recently bought and sold shares of RVNC. Jennison Associates LLC grew its position in Revance Therapeutics by 127.1% during the fourth quarter. Jennison Associates LLC now owns 857,536 shares of the biopharmaceutical company’s stock worth $30,657,000 after buying an additional 480,008 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Revance Therapeutics by 7.3% in the 2nd quarter. Vanguard Group Inc. now owns 931,623 shares of the biopharmaceutical company’s stock worth $24,595,000 after purchasing an additional 63,505 shares in the last quarter. Northern Trust Corp boosted its holdings in shares of Revance Therapeutics by 19.9% in the 2nd quarter. Northern Trust Corp now owns 318,877 shares of the biopharmaceutical company’s stock worth $8,418,000 after purchasing an additional 52,940 shares in the last quarter. Pura Vida Investments LLC purchased a new position in shares of Revance Therapeutics in the 3rd quarter worth about $1,378,000. Finally, EAM Investors LLC boosted its holdings in shares of Revance Therapeutics by 113.9% in the 3rd quarter. EAM Investors LLC now owns 72,518 shares of the biopharmaceutical company’s stock worth $1,998,000 after purchasing an additional 38,621 shares in the last quarter. Institutional investors and hedge funds own 77.84% of the company’s stock.

TRADEMARK VIOLATION WARNING: This news story was originally posted by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this news story on another website, it was copied illegally and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://sportsperspectives.com/2018/02/07/revance-therapeutics-rvnc-downgraded-by-bidaskclub-to-strong-sell.html.

About Revance Therapeutics

Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.

Analyst Recommendations for Revance Therapeutics (NASDAQ:RVNC)

Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply